Transaction overview
Ionis Pharmaceuticals (NASDAQ: IONS) Executive Vice President Brian Birchler reported the sale of 973 shares of common stock on April 16, 2026, in a transaction disclosed on a Form 4 filing with the Securities and Exchange Commission. The disposal generated approximately $73,015, executed at a weighted average price of $75.042. Individual execution prices for the shares ranged from $75.01 to $75.06.
Reason for sale and related vesting
The Form 4 filing indicates the sale was carried out to cover tax withholding obligations that arose on the vesting of restricted stock units. One day prior, on April 15, Birchler recorded the acquisition of 1,875 shares of Ionis common stock, valued at $0, upon the vesting of restricted stock units.
Post-transaction ownership
Following these movements, Birchler holds 67,500 shares of Ionis stock directly. In addition to his outright holdings, he retains 48,926 Restricted Stock Units.
Share price context
At the time the article was prepared, Ionis shares were trading at $75.71. That price represents a 167% gain over the past 12 months. The piece notes that InvestingPro’s analysis suggests the shares could be overvalued at current levels.
Analyst coverage and pricing developments
Several sell-side analysts and firms have weighed in on Ionis amid product and pricing news. Barclays raised its price target to $106 and kept an Overweight rating after Ionis announced a new pricing strategy for Tryngolza, setting the price at $40,000. That figure is materially lower than the previously cited $60,000 price for a comparable drug, Redemplo. William Blair responded to the pricing update by reiterating its Outperform rating.
RBC Capital maintained an Outperform rating and a $95 price target in light of the Tryngolza pricing plan, which is scheduled to take effect in April 2026. Raymond James initiated coverage with an Outperform rating and a $104 price target, citing Tryngolza's potential as a significant upcoming product launch. H.C. Wainwright reaffirmed a Buy rating and set a $120 price target following positive regulatory developments in Europe for Tryngolza, noting supportive data from pivotal Phase 3 trials.
Research access
The article mentions that a comprehensive Pro Research Report on Ionis, along with reports for more than 1,400 other U.S. equities, is available on InvestingPro for investors seeking deeper valuation and financial analysis.
Note on scope
The reporting here is limited to the transactions, ownership totals, share-price context, and analyst actions stated above. Where the original disclosures or filings do not provide additional detail, this article does not expand beyond those reported facts.